Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.

Robert T Dorr, Mary Ann Raymond, Terry H Landowski, Nicholas O Roman, Shoji Fukushima
{"title":"Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.","authors":"Robert T Dorr,&nbsp;Mary Ann Raymond,&nbsp;Terry H Landowski,&nbsp;Nicholas O Roman,&nbsp;Shoji Fukushima","doi":"10.1385/IJGC:36:1:015","DOIUrl":null,"url":null,"abstract":"<p><p>Imexon is an aziridine-containing small molecule currently in Phase I clinical trials. This agent has been shown to bind to thiols and increase intracellular oxidants, inducing apoptosis in hematologic cancer cells. Pancreatic cancers are known to be sensitive to oxidation, suggesting this disease may be an appropriate target for this agent. The current report examines the activity of imexon in pancreatic cells. Imexon induced concentration-dependent and time-dependent apoptosis in a panel of six human pancreatic carcinoma cell (PCC) lines. The mean IC50 (SD) for growth inhibition by the SRB assay was 200 (101) microM for a 48 h exposure with a range of 64-358 microM. Cell killing was schedule-dependent, favoring exposure times > or =48 h. Imexon-treated MiaPaCa-2 cells underwent non-lethal growth arrest following exposure to concentrations < or =200 microM for 48 h. When concentrations were increased to 300 microM for > or =48 h, the MiaPaCa-2 cells arrested in G2 phase and activated caspases 3, 8, and 9 were detected. After a 72 h exposure to the IC80 concentration of imexon, cells exhibited a loss of mitochondrial membrane potential detected by CMXRos staining. However, there was no loss of reduced cellular thiols unless very high concentrations of > or =400 microM were used. In contrast, reactive oxygen species (ROS) were elevated in a dose-dependent fashion, starting at very low imexon concentrations. Imexon also significantly inhibited MiaPaCa-2 tumor growth in SCID mice at 100 mg/kg/d for 9 d. The tumor growth inhibition (% T/C) was 27% of control, and the tumor growth delay was 21 d, indicating an active agent by NCI standards. The levels of imexon that are cytotoxic in human PCC's are achievable based on the preliminary results of the ongoing Phase I trial. Imexon appears to be active against PCCs in vitro and has an entirely novel mechanism of action involving G2 arrest, accumulation of ROS, and the induction of apoptosis.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"36 1","pages":"15-28"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:36:1:015","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of gastrointestinal cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1385/IJGC:36:1:015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Imexon is an aziridine-containing small molecule currently in Phase I clinical trials. This agent has been shown to bind to thiols and increase intracellular oxidants, inducing apoptosis in hematologic cancer cells. Pancreatic cancers are known to be sensitive to oxidation, suggesting this disease may be an appropriate target for this agent. The current report examines the activity of imexon in pancreatic cells. Imexon induced concentration-dependent and time-dependent apoptosis in a panel of six human pancreatic carcinoma cell (PCC) lines. The mean IC50 (SD) for growth inhibition by the SRB assay was 200 (101) microM for a 48 h exposure with a range of 64-358 microM. Cell killing was schedule-dependent, favoring exposure times > or =48 h. Imexon-treated MiaPaCa-2 cells underwent non-lethal growth arrest following exposure to concentrations < or =200 microM for 48 h. When concentrations were increased to 300 microM for > or =48 h, the MiaPaCa-2 cells arrested in G2 phase and activated caspases 3, 8, and 9 were detected. After a 72 h exposure to the IC80 concentration of imexon, cells exhibited a loss of mitochondrial membrane potential detected by CMXRos staining. However, there was no loss of reduced cellular thiols unless very high concentrations of > or =400 microM were used. In contrast, reactive oxygen species (ROS) were elevated in a dose-dependent fashion, starting at very low imexon concentrations. Imexon also significantly inhibited MiaPaCa-2 tumor growth in SCID mice at 100 mg/kg/d for 9 d. The tumor growth inhibition (% T/C) was 27% of control, and the tumor growth delay was 21 d, indicating an active agent by NCI standards. The levels of imexon that are cytotoxic in human PCC's are achievable based on the preliminary results of the ongoing Phase I trial. Imexon appears to be active against PCCs in vitro and has an entirely novel mechanism of action involving G2 arrest, accumulation of ROS, and the induction of apoptosis.

依美克森诱导人胰腺癌细胞系细胞凋亡和细胞周期阻滞。
Imexon是一种含氮嘧啶的小分子药物,目前正处于I期临床试验阶段。该制剂已被证明与硫醇结合并增加细胞内氧化剂,诱导血液学癌细胞凋亡。众所周知,胰腺癌对氧化很敏感,这表明这种疾病可能是这种药物的合适靶点。目前的报告检查了胰细胞中imexon的活性。依咪康诱导6种人胰腺癌细胞(PCC)的浓度依赖性和时间依赖性凋亡。SRB试验对生长抑制的平均IC50 (SD)为200 (101)microM,暴露48 h,范围为64-358 microM。细胞杀伤与时间有关,有利于暴露时间>或=48小时。imexon处理的MiaPaCa-2细胞在暴露于浓度<或=200 microM 48小时后出现非致死生长停滞。当浓度增加到300 microM >或=48小时时,检测到MiaPaCa-2细胞在G2期停滞,并激活了caspases 3、8和9。暴露于IC80浓度的imexon 72小时后,细胞表现出线粒体膜电位的损失,通过CMXRos染色检测。然而,除非使用>或=400微米的非常高浓度,否则不会有还原性细胞硫醇的损失。相比之下,活性氧(ROS)以剂量依赖性的方式升高,从非常低的依美克森浓度开始。100 mg/kg/d的Imexon也能显著抑制SCID小鼠的MiaPaCa-2肿瘤生长,持续9 d,肿瘤生长抑制率(% T/C)为对照的27%,肿瘤生长延迟21 d,为NCI标准的活性药物。根据正在进行的I期试验的初步结果,对人类PCC的细胞毒性水平是可以实现的。Imexon在体外似乎对PCCs有活性,并且具有一种全新的作用机制,包括G2阻滞、ROS积累和诱导细胞凋亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信